Adjuvant pembrolizumab significantly improves disease-free survival (DFS) vs placebo in patients with clear-cell renal cell carcinoma (RCC) who are at risk of disease recurrence after nephrectomy, results of the phase III KEYNOTE-564 study have shown.

Adding the anti–PD-1 monoclonal antibodies toripalimab or camrelizumab to first-line standard of care (SoC) with gemcitabine and cisplatin (GC) significantly improves progression-free survival (PFS) vs GC alone in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC), two phase III trials have shown. These results, reported at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021), may position toripalimab or camrelizumab in combination with GC as a new first-line SoC in this patient population.

First-line treatment with lenvatinib plus pembrolizumab improves progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) vs sunitinib across subgroups of patients with advanced renal cell carcinoma (RCC), and maintains or improves patients’ health-related quality of life (HRQoL), new data from the CLEAR trial have shown.

Treatment with tislelizumab led to a significantly improved overall survival (OS) in patients with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy in the second-line setting, according to the RATIONALE 302* study presented at ASCO 2021.